Key points are not available for this paper at this time.
Design
Review
May support RAS blockade to limit atherosclerosis progression; leaves open dedicated RCTs for plaque-specific outcomes.
The renin-angiotensin system plays a central role in the pathogenesis of cardiovascular disease. At the molecular and cellular levels, angiotensin II, the main effector peptide of the system, stimulates key components of atherosclerosis. Trials in animals and humans indicate that blocking renin-angiotensin system pathways decreases atherosclerotic plaque progression and ischemic events. This review provides a broad overview of the entire role of the renin-angiotensin system in atherothrombotic disease, ranging from molecular pathways to human genetics to the latest clinical trials. Arch Intern Med. 2003;163:1155-1164
No takes yet. Share an insight, caveat, or question.
Jacoby et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: